Method and assay for early diagnosis of prostate cancer
View Patent ↗A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of expression of different galectin isoforms and/or different levels of promoter methylation of such galectin isoforms.
1. A method for determining prostate cancer in a subject, the method comprising:
obtaining a biological sample from the subject;
determining promoter methylation level in said biological sample of Gal3 and Gal8g; and
comparing promoter methylation levels relative to levels found in normal prostate tissue,
wherein a decrease in the level of Gal8g promoter methylation and an increase in the level of Gal3 promoter methylation is an indication of prostate cancer in the subject and wherein the biological sample is selected from prostate tissue, urine and serum.
2. A method for determining Stage II prostate cancer in a subject, the method comprising:
obtaining a biological sample from the subject;
determining promoter methylation level in said biological sample of Gal3; and
comparing promoter methylation level of Gal3 in said biological sample relative to a promoter methylation level of Gal3 in a normal biological sample of a same type,
wherein the level of Gal3 in the sample is heightened Gal3 promoter methylation relative to the Gal3 promoter methylation level in the normal biological sample of a same type, and where the heightened Gal 3 promoter methylation is indicative of Stage II prostate cancer and wherein the biological sample is selected from prostate tissue, urine and serum.
3. A method for determining Stage II prostate cancer in a subject, the method comprising:
obtaining a biological sample from the subject;
determining promoter methylation level in said biological sample by PCR; and
comparing promoter methylation level of Gal3 in said biological sample relative to a promoter methylation level of Gal3 in a normal biological sample of a same type,
wherein the level of Gal3 in the sample is heightened Gal3 promoter methylation relative to the Gal3 promoter methylation level in the normal biological sample of a same type, and where the heightened Gal 3 promoter methylation is indicative of Stage II prostate cancer and wherein the biological sample is selected from prostate tissue, urine and serum.
4. The method of claim 2 , wherein the biological sample is prostate tissue.
5. The method of claim 2 , wherein the biological sample is urine.
6. The method of claim 2 , wherein the biological sample is serum.
7. The method of claim 2 , further comprising comparing the promoter methylation level of Gal3 in said biological sample relative to a promoter methylation level of Gal3 in a Stage III prostate cancer sample of a same type, wherein the Gal3 promoter methylation level in the sample is heightened relative to the Gal3 promoter methylation level in the Stage III prostate cancer sample and wherein the Gal3 promoter methylation level in the Stage III prostate cancer sample is heightened Gal3 promoter methylation relative to the Gal3 promoter methylation level in the normal biological sample.
8. The method of claim 3 , further comprising comparing the promoter methylation level of Gal3 in said biological sample relative to a promoter methylation level of Gal3 in a Stage III prostate cancer sample of a same type, wherein the Gal3 promoter methylation level in the sample is heightened relative to the Gal3 promoter methylation level in the Stage III prostate cancer sample and wherein the Gal3 promoter methylation level in the Stage III prostate cancer sample is heightened Gal3 promoter methylation relative to the Gal3 promoter methylation level in the normal biological sample.